☆ 4.7 Article

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients

INTERNATIONAL JOURNAL OF CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021

Wiktoria Budziar et al.

Summary: This study investigated the population immunity to SARS-CoV-2 among healthy individuals in Poland and found that 35.5% tested positive for SARS-CoV-2-specific IgG and 52.3% tested positive for SARS-CoV-2-specific IgA. Among the participants, 21.2% developed virus-specific IgG or IgA while being asymptomatic.

PLOS ONE (2022)

Add to Collection

Article Oncology

Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors

Maciej Majcherek et al.

Summary: Vaccination against SARS-CoV-2 with the BNT162b2 mRNA vaccine is effective and safe in patients after hematopoietic stem cell transplantation, with a high rate of seroconversion. However, the use of calcineurin inhibitors at the time of vaccination has a negative impact on the humoral response.

CANCERS (2022)

Add to Collection

Article Hematology

Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Ohad Benjamini et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. In this study, the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in CLL patients were investigated. The vaccine was found to be safe, but its efficacy was limited, especially in treated patients.

HAEMATOLOGICA (2022)

Add to Collection

Meeting Abstract Hematology

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Cristina Bagacean et al.

BLOOD (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Review Hematology

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Heinz Ludwig et al.

Summary: Patients with multiple myeloma are at increased risk of infection and mortality related to SARS-CoV-2 virus, and may have suboptimal immune response to vaccination, highlighting the importance of monitoring and adapting vaccination strategies for this vulnerable population.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Immunology

BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype

Gisella Guerrera et al.

Summary: Vaccination with the Pfizer-BioNTech mRNA vaccine induces a sustained anti-viral T cell response for at least 6 months, demonstrating immunological competence and long-term memory against SARS-CoV-2.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Antibodies and Vaccines Target RBD of SARS-CoV-2

Long Min et al.

Summary: Following the outbreak of the pandemic, the development of neutralizing antibodies and vaccines targeting the coronavirus has become crucial, with RBD being identified as the key research target.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Add to Collection

Article Hematology

Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma

Irit Avivi et al.

Summary: This single-centre study found that multiple myeloma (MM) patients had a lower seropositive response rate to the BNT162b2 vaccine compared to healthy controls, with older age, hypogammaglobulinaemia, and exposure to multiple anti-myeloma drugs associated with lower response rates. The vaccine was found to be safe and provide high seropositivity in MM patients independent of treatment type.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Oncology

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma

Oliver Van Oekelen et al.

CANCER CELL (2021)

Add to Collection

Letter Oncology

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Antonio Cuneo et al.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Letter Oncology

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Tamar Tadmor et al.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma

Samuel D. Stampfer et al.

Summary: Patients with multiple myeloma have impaired responses to mRNA vaccination against COVID-19, with those with active disease showing poorer responses. Factors such as age, renal function, immunoglobulin levels, among others, can predict vaccine responsiveness in these patients. Additionally, patients vaccinated with mRNA-1273 had higher anti-spike antibody levels compared to those vaccinated with BNT162b2.

LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange et al.

Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Florent Malard et al.

Summary: This study evaluated the safety and immunogenicity of the BNT162b2 vaccine in patients with hematological malignancies. It found that only around half of the patients may achieve effective immune protection against COVID-19 after receiving two doses of the vaccine. Factors such as being male, receiving B-cell targeting treatment, and having low CD19(+) B-cell levels were associated with a decreased probability of achieving a protective level of anti-S IgG after the second dose.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

H. Parry et al.

Summary: CLL patients have lower antibody responses after both first and second Covid-19 vaccine doses compared to healthy donors. Patients currently treated with BTK inhibitors or with IgA deficiency are more likely to fail to generate an antibody response after the second vaccine. This study supports the need for optimizing vaccination strategies in CLL patients, potentially including the use of booster vaccines.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Oncology

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

David J. Chung et al.

Summary: Patients with hematologic malignancy have compromised COVID-19 vaccine responses at baseline, which are further suppressed by certain therapies, leading to insufficient neutralizing capacity despite positive antibody titers. Refining vaccine response parameters is critical for guiding clinical care, including the consideration for booster vaccines in this vulnerable population.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Article Virology

Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV

Vargab Baruah et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Hematology

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato et al.

BLOOD (2020)

Add to Collection

Article Oncology

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfo et al.

LEUKEMIA (2020)

Add to Collection

Article Hematology

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Ajai Chari et al.

BLOOD (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies

Camille Guillerey et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2016)

Add to Collection

Article Hematology

Perturbation of the normal immune system in patients with CLL

Francesco Forconi et al.

BLOOD (2015)

Add to Collection

Article Oncology

Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

Kimberly Noonan et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.